TCGA based integrated genomic analyses of ceRNA network and novel subtypes revealing potential biomarkers for the prognosis and target therapy of tongue squamous cell carcinoma

Zaiye Li*, Canhua Jiang, Yongxiang Yuan

Department of Oral and Maxillofacial Surgery, Xiangya Hospital, Central South University, Changsha, Hunan, China

* zaiyl01@163.com

Abstract

Objectives

The study aimed to investigate the ceRNA network in biological development of Tongue Squamous Cell Carcinoma (TSCC) and to identify novel molecular subtypes of TSCC to screen potential biomarkers for target therapy and prognosis by using integrated genomic analysis based on The Cancer Genome Atlas (TCGA) database.

Material and methods

Data on gene expressions were downloaded from TCGA and GEO database. Differentially expressed RNAs (DERNAs) were shown by DESeq2 package in R. Functional enrichment analysis of DERNAs was performed using clusterprofilers in R. PPI network was established by referring to String website. Survival analysis of DERNAs was carried out by survival package in R. Interactions among mRNAs, miRNAs and lncRNAs were obtained from Starbase v3.0 and used to construct ceRNA network. Consensus Cluster Plus package was applied to identify molecular subtypes. All key genes were validated by comparing them with GEO microarray data. Statistical analyses of clinical features among different subtypes were performed using SPSS 22.0.

Results

A total of 2907 mRNAs (1366 up-regulated and 1541 down-regulated), 191miRNAs (98 up-regulated and 93 down-regulated) and 1831 lncRNAs (1151 up-regulated and 680 down-regulated) were identified from tumor and normal tissues. A ceRNA network was successfully constructed and 15 DERNAs, 1 DEMiRNA, 2 DElncRNAs associated with prognosis were employed. Furthermore, we firstly identified 2 molecular subtypes, basal and differentiated, and found that differentiated subtype consumed less alcohol and was related to a better overall survival.
Conclusion

The study constructed a ceRNA network and identified molecular subtypes of TSCC, and our findings provided a novel insight into this intractable cancer and potential therapeutic targets and prognostic indicators.

Introduction

Oral squamous cell carcinoma (OSCC), among others, is one of the most frequent cancers in the world. The major type of OSCC is tongue squamous cell carcinoma, the incidence which accounts for 25%~40% [1]. OSCC is characterized by a rapid local invasion, an early lymph node metastasis and a poor prognosis [2]. According to a retrospective analysis by Nair [3], TSCC was clinically different from other oral cancers due to its pathological factors, suggesting that TSCC could be regarded as a particular type of OSCC. The occurrence of TSCC could be attributed to tobacco, alcohol and areca nut [4]. Although great efforts have been made in the advances in surgical techniques, chemo-radiotherapy and some other target therapies, the overall survival of TSCC still hovers around 50% [5]. Thus, it is crucial to reveal the underlying biological mechanism and different molecular subtypes of TSCC associated with prognosis in order to discover novel biomarkers for target therapy and prognosis prediction.

MRNAs and some non-coding RNAs, including microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), play an important role in the initiation and progression of TSCC. MiRNA, which is a family of functional noncoding RNA molecules with a length of 20–25 nucleotides, widely participate in post-transcriptional regulation by targeting mRNAs. A series of miRNAs have been demonstrated as oncogenes or tumor suppressors of TSCC [6,7]. LncRNAs, which are defined as endogenous non-coding RNAs that are longer than 200 nucleotides, regulate biological processes including transcriptional regulation, cell metabolism and RNA modification in tumorigenesis and metastasis of TSCC [8,9]. On the basis of the function of miRNAs and lncRNAs, Salmena et al put forward a hypothesis of competing endogenous RNA (ceRNA) across transcriptome, in which all types of RNA transcripts were believed to be able to act as a ceRNA through microRNA response elements (MREs) that are accessible to microRNA binding [10]. According to such a hypothesis, a great number of studies further demonstrated the importance of ceRNA in the occurrence and development of different cancers. For example, Zhou et al used GEO database to construct a miRNA-mRNA network of TSCC [11]. Nohata et al identified a prognostic lncRNAs malignant progression of TSCC [12]. The ceRNA network of OSCC was first established by Simin Li in 2017 [13]. However, to the best of our knowledge, no study has been conducted on ceRNA network of TSCC.

In addition to the regulation of ceRNA network in carcinogenesis, different clinical or molecular subtypes have been increasingly shown to be associated with different clinical and pathological factors. Walter et al identified 4 gene expression subtypes of head and neck squamous cell carcinoma (HNSCC) [14], and to further expand Walter’s study, Zevallos [15] et al carried out gene expression analysis and demonstrated 4 subtypes to predict nodal metastasis and survival in human papilloma virus (HPV)–negative OSCC. However, we still lack a classification of TSCC subtypes.

Therefore, the aim of present study is to investigate the hidden crosstalk among various RNAs in TSCC via ceRNA network construction and to identify molecular subtypes of TSCC that can be used to predict prognosis. Furthermore, we identified that several genes with differential expressions from tumor and normal tissues were significantly associated with overall
behavior by integrated analysis. Our findings provided a novel insight into the biological process of TSCC and potential biomarkers for target therapy and survival prediction.

Methods and materials

1. Data collection and preprocessing

Gene expression data (RNA sequencing profiles and miRNA profiling) and corresponding clinical data of TSCC were obtained from TCGA database (https://portal.gdc.cancer.gov/), and 126 TSCC samples and 13 normal controlled samples were collected. Among these data, data on mRNA and lncRNA expressions were obtained from Illumina HiSeqRNASeq platform, while miRNA data were collected from Illumina HiSeqmiRNASeq platforms.

RNA sequencing profiles based on TCGA were preprocessed by pre-filtered low count genes (total counts < 10). MRNAs and IncRNAs were encoded according to GENCODE Release 29 (GRCh38.p12) (https://www.gencodegenes.org/human/). miRNAs were annotated based on miRbase v22 (http://www.mirbase.org/index.shtml#opennewwindow).

3 gene expression profiles of TSCC (GSE30784, GSE13601 and GSE28100) were downloaded from Gene Expression Omnibus (GEO) database (http://www.ncbi.nlm.nih.gov/geo/) by searching the term “tongue squamous cell carcinoma” (January 2019). GSE30784 and GSE13601 were determined based on Affymetrix Human Genome U133 Plus 2.0 Array and U95 Version 2 Array. The platform of GSE28100 was Agilent-021827 Human miRNA Microarray (V3) (miRBase release 12.0 miRNA ID version).

2. Identification of differentially expressed mRNAs, miRNAs, and IncRNAs in TSCC

The differentially expressed lncRNA (DElncRNA), mRNA (DEmRNA), miRNA (DEmiRNA) in TSCC samples and normal controlled samples were identified using DESeq2 package of R software (Version 3.8; http://www.bioconductor.org/packages/release/bioc/html/DESeq2.html). P-value was adjusted to false discovery rate (FDR). |log2 fold change (FC) | > 1.5 and P-value < 0.05 were set as the cutoff criteria. The heatmaps were plotted based on pheatmap package of R.

3. Functional enrichment analysis of GO annotation and KEGG Pathways

ClusterProfiler v3.8 package of R was used to analyze and visualize functional profiles (Gene Ontology (GO) annotation and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway) of the genes in order to determine shared functions among DEmRNAs. P < 0.05 was considered as a threshold of GO and KEGG enrichment analysis.

4. Establishment of protein–protein interaction (PPI) network

To understand the underlying interaction of DEmRNAs, the STRING website was employed to construct the PPI network, which was visualized by the Cytoscape software v3.6.1.

5. DEmRNAs, DElncRNAs, and DEmiRNAs associated with prognosis

Survival analysis was carried out by using the survival package of R to help assess the prognostic value of differentially expressed RNAs in TSCC patients. All samples were divided into either the high-expression group (> median) or the low-expression group (< median) in terms of the expression of each DEmRNA, DElncRNA, and DEmiRNA. The Survival curves were plotted using the Kaplan-Meier method. The log-rank test was adopted to assess statistical significance. P < 0.05 was considered as statistically significant.
6. Prediction of lncRNA–miRNA and miRNA–mRNA interactions

We predict the interaction between DElncRNA and DEmiRNA or DEmRNA and DEmiRNA by using starBase v3.0, which determined more than 1.1 million miRNA-ncRNA, 2.5 million miRNA-mRNA and 1.5 million RNA-RNA interactions from multi-dimensional sequencing data. In addition, the prediction results of miRanda, Targetscan and miRmap were integrated by starBase. Only the regulatory pairs of DEmiRNAs and DEGs, DElncRNAs and DEmiRNAs had opposite expressions and were therefore included in the present study.

7. Construction of ceRNAs regulatory network

According to ceRNA theory, the selected interaction of DEmiRNAs and DEmRNAs and of DElncRNAs and DEmiRNAs were integrated to construct the DElncRNAs-DEmiRNAs-DEmRNAs ceRNA network using Cytoscape software v3.6.1.

8. Validation of expressions of crucial DEmRNAs, DElncRNAs, and DEmiRNAs basing on ceRNA network and prognosis analysis

GEO2R (http://www.ncbi.nlm.nih.gov/geo/geo2r/) is an interactive web analysis tool for GEO data to identify genes with differential expressions among different groups provided by GEO database. We applied GEO2R to confirm key RNAs. Crucial DEmRNAs and DElncRNAs were verified in GSE30784 and GSE13601 and GSE28100 was used to validate crucial DEmiRNAs.

9. Copy number variations (CNV), somatic mutation (SNV) and methylation analysis of hub genes

To determine the possible regulatory mechanism of crucial RNAs with differential expressions from TSCC and normal tissue, CNV and methylation data analysis on selected RNAs were performed by cor package of R software. Pearson correlation analysis was carried out to identify whether they had correlated relationship with Pearson correlation coefficient $>0.40$, which was set as a cutoff. SNV analysis was performed to excavate whether there existed some mutations of genes that possibly regulated genes, which were most significantly related to prognosis, by using Fisher test. P value $<0.05$ was considered as statistically significant.

10. Molecular subtypes of TSCC classification

To find out if some molecular subtypes of TSCC were associated with prognosis, we classify TSCC subtypes in terms of gene expression from TCGA using ConsensusClusterPlus package of R. The top 2000 variable genes were reduced for integrative clustering analysis by median absolute deviation. All sample were divided into k (2 to 6) groups for determining a stable classification by k value analysis.

11. Clinical features description and survival analysis of different subtypes

Clinical information (i.e. clinical stage, T stage, N stage, smoking history, alcohol history, nodal extracapsular spread) was collected. Chi-square test was used to assess statistical significance between each subtype with $p<0.05$, which was set as the cut-off criterion. Survival analyses of patients with different subtypes were performed subsequently using a log-rank test by survival package of R. P value $<0.05$ was set as a threshold.
12. Identification of differential expression of mRNAs, miRNAs, lncRNAs between different subtypes of TSCC associated with prognostic DERNAs and functional enrichment analysis of GO and KEGG

To understand the intrinsic biological features between different molecular subtypes, we identified mRNAs, lncRNAs and miRNAs with differential expressions. Among these DERNAs, genes overlapped with prognostic genes mentioned above were considered as potential prognostic predictors for TSCC, according to different subtypes. Functional enrichment analyses were carried out to excavate biological mechanism and to define gene expression subtypes by clusterprofiler mentioned above. P<0.05 was considered as a cutoff of GO and KEGG enrichment analysis.

Results

1. DElncRNAs, DEmiRNAs, and DEmRNAs in TSCC

A total of 2907 mRNAs (1366 up-regulated and 1541 down-regulated), 191miRNAs (98 up-regulated and 93 down-regulated) and 1831 lncRNAs (1151 up-regulated and 680 down-regulated) were identified in mRNA-seq and miRNA-seq data between |log2 fold change (FC)| >1.5 and P value < 0.05. RNAs with differential expressions were visualized in heatmap (Fig 1). Top 10 DElncRNAs, DEmiRNAs and DEmRNAs were list in Table 1.

2. Functional enrichment analysis of gene ontology and KEGG pathways

2907 DEmRNAs were involved in the functional enrichment analysis using clusterProfiler package of R. GO annotation consists of biological process (BP), cellular component (CC), molecular function (MF). The top 50 GO analyses results were list in S1 Table. These results

---

Fig 1. Heatmap of top 100 variable of differentially expressed RNAs between TSCC and non-tumor tissues. (A) DElncRNAs, (B) DEmiRNAs, (C) DEmRNAs.

https://doi.org/10.1371/journal.pone.0216834.g001
(Fig 2) revealed that DEmRNAs were enriched in 1313 BPs, most of which took part in extra-cellular organization, ion transmembrane transport, muscle biological process and epidermal cell differentiation. MF analysis indicated that these DEmRNAs were significantly associated with 257 MFs, including channel activity, DNA-binding transcription activator activity, RNA polymerase II-specific, actin binding, enzyme inhibitor activity and cytokine activity. We found that the most enriched CC was collagen-containing extracellular matrix. KEGG pathway analysis (Fig 2 and S2 Table) showed that a total of 50 pathways were highly enriched, which was consistent to DEmRNAs. These pathways were mainly involved in Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Human papillomavirus infection, Focal adhesion and Calcium signaling pathway.

3. Protein-protein network analysis

Based on DEmRNAs, 12872 pairs of mRNA interaction relationship were identified using the STRING database with scores of >0.4. Genes, whose number of edges were larger than 50,
Fig 2. The top 10 enrichment scores in KEGG pathway and GO enrichment analysis of the DEmRNA. (A) Biological process of DEmRNAs; (B) Molecular function of DEmRNAs; (C) cellular component of DEmRNAs; (D) KEGG pathway of DEmRNAs.

https://doi.org/10.1371/journal.pone.0216834.g002
were employed in PPI network (S3 Table). 77 mRNAs were therefore selected to construct PPI network (Fig 3) using Cytoscape. The gene with the highest degree was ALB (Degree = 217), and ITGAX was the gene with the highest combined score (Combined score = 0.932).

4. Prognostic overall survival assessment of DEmRNAs, DEmiRNAs, and DElncRNAs

The survival analysis was performed to evaluate the prognostic signatures of DEmRNAs, DEmiRNAs, and DElncRNAs. Setting P<0.05 as a cutoff, a total of 154 DEmRNAs, 6
DEmiRNAs, 76 DElncRNAs were significantly related to overall survival. Among these potential prognostic biomarkers, a low expression of NAGS, which was the gene the most significantly associated with survival ($P = 0.00036$), was positively related to OS. For DEmiRNAs, a low expression of hsa-miR-1229-3p linked the most significantly to a high OS ($P = 0.0053$). However, a low expression of AL359851.1 the most significantly suggested a longer survival time, with a $P = 0.00096$ in DElncRNAs. The 3 biomarkers that were the most significantly related of each type of DERNAs were presented in Fig 4. All survival analysis results were given in S4 Table.

5. CeRNAs regulatory network construction

StarBase v3.0 was used to match DEmiRNAs and DEmRNAs or DElncRNAs. A total of 358 pairs of DEmiRNA-DEmRNA interactions (S5 Table) combined by 26 DEmiRNAs and 185 DEmRNAs were successfully predicted. In miRNA-ncRNA interaction analysis, 23 DEmiRNAs and 22 DElncRNAs were involved in 44 pairs of DEmiRNA-DElncRNA interactions (S6 Table). All the interactive pairs were integrated to construct the lncRNA-miRNA-mRNA ceRNA network (Fig 5), which contained 249 nodes and 409 edges, using cytoscape software.

To identify critical DERNAs that played an important part in both biological process and prognosis, we screened prognostic DERNAs that were involved in ceRNA network. Finally, we obtained 15 DEmRNAs(SLC16A1, E2F7, SCN8A, ZIC2, NR4A1, CLU, GFPT2, CEP55, PLK1, SYBU, STC2, DEPDC1B, MICB, LIFR, BIRC5), 1DEmiRNA(hsa-miR-337-3p) and 2 DElncRNAs(AC017048.3, AC156455.1) l. The result suggested that these RNAs were particularly crucial for the occurrence, development and prognosis of TSCC.

https://doi.org/10.1371/journal.pone.0216834.g004

Fig 4. Kaplan-Meier survival plots of the top 3 prognostic RNAs: (A) NAGSKM-plot for median threshold; (B) SOHLH1 KM-plot for median threshold; (C) ETNPPL KM-plot for median threshold; (D) hsa-miR-1229-3p KM-plot for median threshold; (E) hsa-miR-654-3p KM-plot for median threshold; (F) hsa-miR-377-3p KM-plot for median threshold; (G) AL359851.1 KM-plot for median threshold; (H) LINC02560 KM-plot for median threshold; (I) AC009226.1 KM-plot for median threshold.
Fig 5. The ceRNA network of lncRNA-miRNA-mRNA in TSCC. Diamond represent lncRNA, rounded rectangles indicate miRNA, and ellipses indicate mRNA. The size of nodes represents number of edges. Red nodes indicate up-regulation while blue nodes indicate down-regulation. Different shades of color represent different levels of expression.

https://doi.org/10.1371/journal.pone.0216834.g005
6. Validation of expressions of crucial DEmRNAs, DE-miRNAs, and DE-lncRNAs

To further confirm the biological function and prognostic value of the DEmRNAs, DE-miRNAs and DE-lncRNAs, we used GEO2R to analyze 3 GEO data (GSE30784, GSE13601 and GSE28100). SYBU, AC017048.3 and LOC100506691 were demonstrated to be non-differentially expressed in none of the mRNA microarrays. However, others were validated in at least one data (Table 2).

7. CNV methylation and SNV analysis of hub genes

As 15 DEmRNAs mentioned above had been demonstrated as playing an important role in the development and prognosis of TSCC, we aimed to find the underlying regulatory mechanism. Methylation analysis did not show any gene whose methylation was negatively correlated with its gene expression level, by using cor package of R. However, the expression of GFPT2 (Pearson’s correlation coefficient = 0.436363) was possibly to be positively correlated with its CNV. SNV analysis of the most significant prognostic gene, NAGS, identified FAT1 (p = 0.039) as a potential SNV locus that regulate the gene expression of NAGS.

8. Molecular subtypes of TSCC classification

As DEmRNAs actively participated in TSCC onset and development, we speculated if there were some intrinsic gene expression subtypes related to different prognoses in TSCC. The 2000 most variable genes were employed by variance filtering (MAD method). The output of ConsensusClusterPlus showed k (2 to 6) clusters (Fig 6), and we calculated cluster-consensus and item-consensus results, which were visualized in Fig 6. All samples were successfully
categorized into 2 subtypes in terms of the most stable k value, and such a process resulted in the removal of 66 out of 126 samples from subtype A and 60 out of 126 samples from subtype B.

9. Clinical characteristics description and prognostic assessment

The clinical characteristics was described, and the results (Table 3) revealed no correlation of TSCC molecular subtype with clinical features such as gender, onset age, pathologic N or T stage, clinical stage and smoking. Noticeably, the patients in group A had a longer drink history (p = 0.024) and more alcohol consumption per day (p = 0.006). Kaplan-Meier survival curve in two subtypes (Fig 7) indicated that subtype B was significantly associated with a better overall survival (p = 0.0039).

10. Identification of differential expression of mRNAs, miRNAs, lncRNAs between different subtypes of TSCC overlapping with prognostic DERNAs and functional enrichment analysis of GO and KEGG

After performing DESeq2 package, 715 DEmRNAs, 7 DEmiRNAs and 521 DElncRNAs were screened. Top 10 DEmRNAs between two subtypes were list in Table 4. Morpheus website was
### Table 3. Clinical features of molecular subtypes.

| Subtype                          | 1                  | 2                  | P Value |
|----------------------------------|--------------------|--------------------|---------|
| Pathologic N stage               |                    |                    | 0.697   |
| N0                               | 34 (51.5%)         | 30 (50.0%)         |         |
| NX                               | 1 (1.5%)           | 2 (3.3%)           |         |
| N1                               | 11 (16.7%)         | 13 (21.7%)         |         |
| N2                               | 20 (30.3%)         | 15 (25%)           |         |
| Pathologic T stage               |                    |                    | 0.137   |
| TX                               | 1 (1.5%)           | 1 (1.7%)           |         |
| T1                               | 3 (4.5%)           | 8 (13.3%)          |         |
| T2                               | 27 (40.9%)         | 23 (38.3%)         |         |
| T3                               | 21 (31.8%)         | 22 (36.7%)         |         |
| T4                               | 14 (21.2%)         | 6 (10.0%)          |         |
| Clinical stage                   |                    |                    | 0.193   |
| 1                                | 2 (3.0%)           | 7 (11.7%)          |         |
| 2                                | 20 (30.3%)         | 15 (25%)           |         |
| 3                                | 16 (24.2%)         | 18 (30%)           |         |
| 4                                | 27 (40.9%)         | 19 (31.7%)         |         |
| x                                | 1 (1.5%)           | 1 (1.67%)          |         |
| Smoking                          |                    |                    | 0.131   |
| Never1                           | 19 (28.8%)         | 25 (41.7%)         |         |
| Former2                          | 25 (37.9%)         | 13 (21.7%)         |         |
| Current3                         | 6 (9.1%)           | 10 (16.7%)         |         |
| 4                                | 14 (21.2%)         | 12 (20%)           |         |
| Missing                          | 2 (3.0%)           | 0                  |         |
| Smoking years                    |                    |                    | 0.053   |
| Never                            | 19 (28.8%)         | 25 (41.7%)         |         |
| 1–20                             | 2 (3.0%)           | 6 (10%)            |         |
| 20–30                            | 4 (6.1%)           | 5 (8.3%)           |         |
| 30–                               | 29 (43.9%)         | 19 (31.7%)         |         |
| Missing                          | 12 (18.2%)         | 5 (8.3%)           |         |
| Alcohol                          |                    |                    | 0.024   |
| Yes                              | 49 (74.2%)         | 33 (55.0%)         |         |
| No                               | 17 (25.8%)         | 27 (45.0%)         |         |
| Alcohol consumption per day      |                    |                    | 0.006   |
| 0                                | 22 (33.3%)         | 34 (56.7%)         |         |
| 1–5                              | 24 (36.4%)         | 10 (16.7%)         |         |
| 5–                               | 2 (3.0%)           | 6 (10.0%)          |         |
| missing                          | 18 (27.3%)         | 10 (16.7%)         |         |
| Gender                           |                    |                    | 0.254   |
| Male                             | 46 (69.7%)         | 36 (60.0%)         |         |
| Female                           | 20 (30.3%)         | 24 (40.0%)         |         |
| Onset age                        |                    |                    | 0.55    |
| 15–30                            | 2 (3.0%)           | 5 (8.3%)           |         |
| 30–50                            | 12 (18.2%)         | 13 (21.7%)         |         |
| 50–70                            | 42 (63.6%)         | 34 (56.7%)         |         |
| 70–                              | 10 (15.2%)         | 8 (13.3%)          |         |
| Pathological nodal extracapsular spread |                    |                    | 0.033   |
| Yes                              | 14 (21.2%)         | 10 (16.7%)         |         |

(Continued)
applied for plotting the heatmap of DEmRNAs (Fig 8). The 3 most upregulated genes were BPIFB2, CTCFL and NTS in subtype A, while DEFB4B, CRNN and MUC21 were the 3 most up-regulated genes in subtype B. DERNAs, 25 mRNAs, 5lncRNAs and 0 miRNA were found to overlapped with prognostic RNAs mentioned above (Table 5). Further enrichment analysis (S7 Table) showed that upregulated genes in subtype A were highly enriched not only in metabolic process, digestion and multicellular organismal homeostasis in GO, but also in chemical carcinogenesis, metabolism by cytochrome P450 and in nicotine addiction in KEGG (Fig 9). However, upregulated genes in group B (S8 Table) was involved in GO including keratinocyte or epidermal cell differentiation, skin or development, peptide cross-linking and cell killing and KEGG, including lipid or acid metabolism and IL-17 signal pathway. Therefore, we termed these two subtypes ‘basal’ and ‘differentiated’ in terms of their particular differential expression gene functions and literature reviews.

Discussion

TSCC, which is the most common kind of OSCC, is generally characterized by a notably aggressive biological behavior and a poor survival. It is urgent to detect the underlying genetic pathogenesis and to find reliable therapeutic targets and prognostic biomarkers for TSCC in order to improve patients’ clinical outcome. In this study, we used TCGA database to identify mRNAs, miRNAs, IncRNA with differential expressions between TSCC and normal control tissues. To further understand the DERNAs, GO and KEGG analysis were performed subsequently. The results of GO analysis showed that extracellular matrix organization, extracellular structure organization, muscle contraction, regulation of ion transmembrane transport and muscle system process were involved in the biological process of TSCC initiation, which was different from other GO types of OSCC [16,17]. This suggested TSCC might be a special type of OSCC, which might be resulted from particular anatomical and histological structure of the tongue. Moreover, the enriched KEGG pathway was found to be involved in cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, HPV infection, alcoholism, focal adhesion, MAPK signaling pathway and cAMP signaling pathway, which was consistent with findings from other previous studies on the tumorigenesis of TSCC [18,19]. We next constructed the PPI network with DEmRNAs and obtained the hub genes with the highest degree including ALB, FN1, EGF, MM9, KNG1, COL1A1, SPP1, ACTN2, most of which were reported to play a critical role in carcinogenesis and tumor progression [20–23].

The ceRNA network was established by integrating all DERNAs. A total of 15 prognostic DEmRNAs (SLC16A1, E2F7, SCN8A, ZIC2, NR4A1, CLU, GFPT2, CEP55, PLK1, SYBU, STC2, DEPDC1B, MICB, LIFR, BIRC5), 1 DEmiRNA(hsa-miR-337-3p) and 2 DElncRNAs (AC017048.3, AC156455.1) were involved in ceRNA network. We investigated the underlying mechanism of mRNA with differential expression, and apart from GFPT2, no correlation was identified between CNV or methylation and gene expression, which provided foundation for intensive study in future. SNV analysis of NAGS (the most significant prognostic gene) indicated that somatic mutation in FAT1 (atypical cadherin 1) may be associated with the dysregulation of NAGS. According to Pickering, FAT1 was mutated in 30% of OSCC samples, which was also the highest frequency of mutation in HNSCC [24,25]. Researchers also suggested that
FAT1 inhibited migration and invasion in OSCC and some other types cancers [26,27]. In this study, FAT1 mutation was shown to be related to differential expression of NAGS, which resulted in a remarkable variation of overall survival. All these results suggested that FAT1 could be used as a novel candidate tumor suppressor or prognostic predictor.

SLC16A1(solute carrier family 16 member 1), alternatively known as MCT, is the most significant prognostic DemRNA employed in ceRNA network and might have the potential to be

**Fig 7.** KM plot of 2 molecular subtypes of TSCC.

https://doi.org/10.1371/journal.pone.0216834.g007

| Symbol  | Log2FoldChange | Pvalue       | High expression in which subtype |
|---------|----------------|--------------|----------------------------------|
| BPIFB2  | -6.12855       | 1.75E-10     | A                                |
| DEFB4B  | 5.844115       | 2.73E-21     | B                                |
| CTCFL   | -5.78405       | 1.47E-16     | A                                |
| NTS     | -5.5462        | 5.91E-27     | A                                |
| BPIFB1  | -5.41866       | 6.25E-20     | A                                |
| CRNN    | 5.009013       | 2.23E-22     | B                                |
| CYP26A1 | -4.70985       | 3.56E-16     | A                                |
| MUC5B   | -4.47367       | 7.41E-20     | A                                |
| MUC21   | 4.343534       | 6.98E-15     | B                                |
| MUC2    | -4.32957       | 2.87E-25     | A                                |

https://doi.org/10.1371/journal.pone.0216834.t004
an important biomarker of survival prediction and therapeutic target in TSCC. Recent studies have confirmed our speculation, Voelxen found that tumor samples from OSCC patients had significantly elevated relative expression levels of MCT [28]. Susana et al. suggested that MCT might be a prognostic molecule of OSCC [29]. E2F7 (transcription factor 7), targeted by MIR424, miR-3666 and miR-26a, is highly expressed in multiple tumors [30,31] such as endometrial carcinoma, breast cancer, colorectal cancer and glioma, indicating that E2F7 might constitute a potential therapeutic target. The overexpression of E2F7 was also detected in
HNSCC [32]. It was also found that Sphk1-dependent activation of AKT mediated E2F7-induced doxorubicin resistance, which might be similar to the mechanism of progression in TSCC. SCN8A (sodium voltage-gated channel alpha subunit 8), which is related to different types of cancers [33,34] including colorectal cancer, prostate cancer, breast and some other types of cancer, emerges as an aggressive oncogene and could cause poor prognosis [35]. ZIC2 (Zic family member 2) has been reported to be crucial to the progression of cancer [36–38] such as hepatocellular carcinoma, epithelial ovarian tumor, osteosarcoma and OSCC. ZIC2 could activated the PI3K/AKT signal pathway, which played a vital role in TSCC, as it promotes viability, migration, and invasion of cancer cells. Sakuma [38] et al. detected that a significant up-regulation of ZIC2 in OSCC samples was related to a poor survival rate. NR4A1 (nuclear receptor subfamily 4 group A member 1) was validated to be targeted by miR-377 [39] and PCH4 [40] and act as a tumor promoter in OSCC. Besides, Liu and Chen [41,42] discovered that NR4A1 could be a critical general regulator in the induction of T cell dysfunction and inhibit NR4A, thus, NR4A1 was seen as promising in cancer immunotherapy. The prognostic DEMiRNA, hsa-miR-337-3p targeting one DEMRNA (AMOT, a witnessed oncogene in OSCC [43]), has been implicated to target AMOT, HOXB7 [44], MMP-14 [45], PTEN [46] and other genes.

### Table 5. DEMiRNAs between two subtypes related to prognosis.

| Symbol          | logFC       | P value of survival analysis |
|-----------------|-------------|-------------------------------|
| SOHLH1          | -4.108109034| 0.000401198                   |
| TGM5            | 1.856189234 | 0.001104156                   |
| ODF4            | 1.83110008  | 0.002145965                   |
| SPINK7          | 4.11976683  | 0.004824705                   |
| FUT6            | 1.522467309 | 0.00743154                    |
| RNF224          | 1.914806608 | 0.008302427                   |
| CNFN            | 2.680331441 | 0.010640736                   |
| PNCK            | -2.685197192| 0.016092106                   |
| PCP4            | -1.814741921| 0.017260067                   |
| FAM25A          | 2.833964095 | 0.01735488                    |
| HPN             | -2.256573085| 0.019961787                   |
| SPRR2E          | 2.816019954 | 0.02093855                    |
| CLDN17          | 2.912792033 | 0.020322063                   |
| S100A9          | 2.13252753  | 0.024516409                   |
| SLC2A14         | -1.68362504 | 0.026262725                   |
| LEXM            | 2.217909192 | 0.028836265                   |
| CRC1T           | 2.901957091 | 0.028858706                   |
| TGM7            | 2.44775921 | 0.030069596                   |
| MAL             | 3.924051739 | 0.033186621                   |
| CCDC187         | -2.418284944| 0.037448993                   |
| SPRR2A          | 2.669076678 | 0.037724674                   |
| CCDC155         | -2.442240546| 0.047564285                   |
| C9orf152        | -2.351492462| 0.048737265                   |
| SLC9A2          | -2.31320548 | 0.049015                      |
| SPINK6          | 3.219429317 | 0.049538758                   |
| LIN02560        | 1.76588842  | 0.001813109                   |
| LIN02028        | 2.121778242 | 0.016551484                   |
| LOC349160       | -1.806825885| 0.023342443                   |
| LIN02487        | 1.783316228 | 0.032572701                   |
| LOC101927503    | -1.858832402| 0.04787                       |

https://doi.org/10.1371/journal.pone.0216834.t005
and acted as a tumor suppressor through sponging oncogene. Loss of miR-337-3p expression was associated with the development of cancer [47]. Most of these DERNAs were demonstrated to participate in carcinogenesis and progression in existing studies. However, the underlying functions of the 2 prognostic DElncRNAs in cancer remain poorly understood.

To further explore the possible genetic classification of TSCC, we identified 2 molecular subtypes in TSCC and termed these 2 subtypes basal and differentiated, according to gene function and Pickering’s work on integrative genomic analysis of OSCC [48]. We integrated the clinical data of the 2 subtypes, interestingly, we found that basal tumors were highly associated with alcohol consumption but a poor clinical outcome. Moreover, the basal tumors were likely to come from patients with a smoking habit. All these clinical features suggested that alcohol and tobacco participate in critical progression of TSCC, therefore leading to a worse prognosis. In addition, we obtained 715 DEmRNAs, 7 DEmiRNAs, 521DElncRNAs. The functional analysis results suggested that basal tumor was expected to be related to metabolic process, chemical carcinogenesis and nicotine addiction, which could explain its different clinical manifestation. However, differentiated tumor was shown to participate in keratinocyte or epidermal cell differentiation, skin or epithelial development, peptide cross-linking, cell killing and IL-17 signal pathway, which were similar to the features characterized by a previous study on differentiated subtype [49]. These findings contributed to a better understanding on the difference of clinical characteristics and the underlying biological mechanism between different subtypes of TSCC.

Among these DERNAs, 25 mRNAs and 5lncRNAs were significantly correlated to prognostic RNAs and had a potential to act as predicted biomarkers to evaluate prognosis. These findings are mostly consistent with the results of previous studies. ODF4 (outer dense fiber of sperm tails 4) has been reported to have a high expression [50] in breast cancer, prostate cancer, basal cell carcinoma and chronic myeloid lymphoma. Afsharpad [51] determined ODF4 expression in urinary exfoliated cells, cancerous tissue and tumor-free tissue to confirm its diagnostic and surveillance potential. SPINK7 (serine peptidase inhibitor, Kazal type 7
(putative) targeted by miR-1322\cite{52} by inhibiting invasion of cancer cells via the urokinase-type plasmin activator receptor 1 integrin pathway or by upregulating p53 expression was considered as a tumor suppressor in multiple types cancers\cite{53-55}. Li et al\cite{56} validated the predictive value of SPINK7 in noninvasive early detection of gastric cancer. Therefore, it is possible to predict prognosis of TSCC patients by detecting SPINK7 expression in saliva. The dysregulation of LINC02487, alternatively known as LOC441178, was detected by transcriptome analysis and verified by RT-PCR in OSCC\cite{57}. Xu\cite{58} et al found that LINC02487 could sponge coiled-coil-containing protein kinase 1 (ROCK1) in OSCC, and that OSCC patients with a high expression of LINC02487 would have a longer survival time, which was in accordance with our result and also suggested that LINC02487 could be a new therapeutic target and prognostic indicator for TSCC. To the best of our knowledge, no relevant studies found that LINC02028, LOC101927503, LOC349160 and LINC02560 existed in cancer. With the advance of RNA sequencing and bioinformatic analysis, a large amount of genomic data become available but requires to be decoded. In our study, we found that 15 DEmRNAs, 1 DEmiRNA, 2 DElncRNAs were related to prognosis by constructing ceRNA network of TSCC. Most of them were found to act as oncogenes or tumor suppressors in many types of cancer, and the analysis of GO and KEGG pathway and PPI network further confirmed their function. Combining the ceRNA network theory, we considered that these DERNAs played a critical role in the occurrence of TSCC and could be utilized as biomarkers for target therapy. Additionally, we firstly confirmed 2 molecular subtypes in TSCC using data from TCGA by clustering analysis, and such an effort helped comprehend the intrinsic classification of TSCC and specific biological process of each subtype. We correlated DEmRNAs between basal and differentiated tumor with prognosis, and 25 mRNAs and 5 lncRNAs were identified to be associated with prognosis. Evidence suggested that these critical molecules not only participated in the initiation, but also in the development of TSCC and helped deciding prognosis and therapy decision. Advances and limitations of this study should also be acknowledged. It should be noticed that we integrated several categories of genetic data to bring out the importance of these selected molecules at different regulatory levels, which has hardly been done in previous studies. However, the data from TCGA only included American samples, which could not represent the whole existing conditions and as the regulatory pathway of molecular is very intricate, what we found in the study may be the tip of an iceberg. Thus, the mechanism of TSCC or even in all types of cancer still has an immense potential to be discovered, and further clinical trials and molecular experiments are required to verify our results.

**Conclusion**

The TCGA-based comprehensive genomic analyses successfully established a ceRNA network of TSCC and defined 2 intrinsic molecular subtypes of TSCC. Furthermore, we demonstrated key molecules involved in carcinogenesis and progression by integrating results of analyses of ceRNA network, overall survival and subtype classification. These discoveries provided a novel genetic landscape and the foundation for prognostic prediction or for more effective treatment, in which key genes are checked and targeted by specific inhibitors or promotors.

**Supporting information**

S1 Table. GO analyses of DEmRNAs.

S2 Table. KEGG pathways of DEmRNAs.
S3 Table. PPI network nodes of DEmRNAs.
(DOCX)

S4 Table. Survival analyses of DERNA.
(DOCX)

S5 Table. 358 pairs of DEmiRNA-DEmRNA interactions.
(DOCX)

S6 Table. 44 pairs of DEmiRNA-DElncRNA interactions.
(DOCX)

S7 Table. Functional enrichment analyses of GO and KEGG in subtype A.
(DOCX)

S8 Table. Functional enrichment analyses of GO and KEGG in subtype B.
(DOCX)

Author Contributions
Conceptualization: Yongxiang Yuan.
Data curation: Canhua Jiang.
Formal analysis: Canhua Jiang, Yongxiang Yuan.
Investigation: Yongxiang Yuan.
Methodology: Canhua Jiang.
Project administration: Yongxiang Yuan.
Software: Zaiye Li.
Supervision: Zaiye Li.
Validation: Zaiye Li.
Visualization: Zaiye Li.
Writing – original draft: Zaiye Li, Canhua Jiang.
Writing – review & editing: Yongxiang Yuan.

References
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016; 66: 7–30. https://doi.org/10.3322/caac.21332 PMID: 26742998
2. Ion Ciucă Mărășescu FI, Marasescu PC, Matei M, Florescu AM, Margaritescu C, Petrescu SMS, et al. Epidemiological and Histopathological Aspects of Tongue Squamous Cell Carcinomas- Retrospective Study. Curr Health Sci J. 2018; 44: 211–224. https://doi.org/10.12865/CHSJ.44.03.03 PMID: 30647940
3. Nair S, Singh B, Pawar PV, Datta S, Nair D, Kane S, et al. Squamous cell carcinoma of tongue and buccal mucosa: clinico-pathologically different entities. Eur Arch Otorhinolaryngol. 2016; 273: 3921–3928. https://doi.org/10.1007/s00405-016-4051-0 PMID: 27098612
4. Gupta B, Johnson NW. Systematic review and meta-analysis of association of smokeless tobacco and of betel quid without tobacco with incidence of oral cancer in South Asia and the Pacific. PLoS One. 2014; 9: e113385. https://doi.org/10.1371/journal.pone.0113385 PMID: 25411778
5. Kokemüller H, Rana M, Rublack J, Eckardt A, Tavassol F, Schumann P, et al. The Hannover experience: surgical treatment of tongue cancer—a clinical retrospective evaluation over a 30 years’ period. Head Neck Oncol. 2011; 3: 27. https://doi.org/10.1186/1758-3284-3-27 PMID: 21600000
6. Wong TS, Liu XB, Wong BY, Ng RW, Yuen AP, Wei WI. Mature miR-184 as Potential Oncogenic microRNA of Squamous Cell Carcinoma of Tongue. Clin Cancer Res. 2008; 14: 2588–92. https://doi.org/10.1158/1078-0432.CCR-07-0666 PMID: 18451220

7. Sun L, Yao Y, Liu B, Lin Z, Lin L, Yang M, et al. MiR-200b and miR-15b regulate epithelial-mesenchymal transition in human tongue cancer cells by targeting BMI1. Oncogene. 2012; 31: 432–45. https://doi.org/10.1038/onc.2011.263 PMID: 21725369

8. Jia LF, Wei SB, Gan YH, Guo Y, Gong K, Mitchelson K, et al. Expression, regulation and roles of miR-26a and MEG3 in tongue squamous cell carcinoma. Int J Cancer. 2014; 135: 2282–93. https://doi.org/10.1002/ijc.28667 PMID: 24343426

9. Wang ZY, Hu M, Dai MH, Xiong J, Zhang S, Wu HJ, et al. Upregulation of the long non-coding RNA AFAP1-AS1 affects the proliferation, invasion and survival of tongue squamous cell carcinoma via the Wnt/β-catenin signaling pathway. Mol Cancer. 2018; 17: 3. https://doi.org/10.1186/s12943-017-0752-2

10. Salmena L, Poliseno L, Tay Y, Kats L, Pandolfi PP. A ceRNA hypothesis: The Rosetta Stone of a hidden RNA language?. Cell. 2011; 146: 353–8. https://doi.org/10.1016/j.cell.2011.07.014 PMID: 21802130

11. Zhou XL, Wu JH, Wang XJ, Guo FJ. Integrated microRNA-mRNA analysis revealing the potential roles of microRNAs in tongue squamous cell cancer. Mol Med Rep. 2015; 12: 885–94. https://doi.org/10.3892/mmr.2015.3467 PMID: 25760063

12. Nohata N, Abba MC, Gutkind JS. Unraveling the oral cancer lncRNAome: Identification of novel lncRNAs associated with malignant progression and HPV infection. Oral Oncol. 2016; 59: 58–66. https://doi.org/10.1016/j.oraloncology.2016.05.014 PMID: 27424183

13. Li S, Chen X, Liu X, Yu Y, Pan H, Haak R, et al. Complex integrated analysis of lncRNAs-miRNAs-mRNAs in oral squamous cell carcinoma. Oncol Rep. 2017; 73: 1–9. https://doi.org/10.1016/j.oralrepon.2017.07.026 PMID: 28939059

14. Walter V, Yin X, Wilkerson MD, Cabanski CR, Zhao N, Du Y, et al. Molecular subtypes in head and neck cancer exhibit distinct patterns of chromosomal gain and loss of canonical cancer genes. PLoS One. 2013; 8: e56823. https://doi.org/10.1371/journal.pone.0056823 PMID: 23451093

15. Zevallos JP, Mazul AL, Walter V, Hayes DN. Gene Expression Subtype Predicts Nodal Metastasis and Survival in Human Papillomavirus-Negative Head and Neck Cancer. Laryngoscope. 2019; 129: 154–161. https://doi.org/10.1002/lary.27340 PMID: 30247749

16. Kumar R, Samal SK, Routray S, Dash R, Dixit A. Identification of oral cancer related candidate genes by integrating protein-protein interactions, gene ontology, pathway analysis and immunohistochemistry. Sci Rep. 2017; 7: 2472. https://doi.org/10.1038/s41598-017-02522-5 PMID: 28559456

17. Zhang X, Zhang L, Tan X, Lin Y, Han X, Wang H, et al. Systematic analysis of genes involved in oral cancer metastasis to lymph nodes. Cell Mol Biol Lett. 2018; 23: 53. https://doi.org/10.1186/s11658-018-0120-2 PMID: 30459815

18. Wang K, Lin C, Wang C, Shao Q, Gao W, Song B, et al. Silencing Kif2a induces apoptosis in squamous cell carcinoma of the oral tongue through inhibition of the PI3K/Akt signaling pathway. Mol Med Rep. 2014; 9: 273–78. https://doi.org/10.3892/mmr.2013.1804 PMID: 24248467

19. Jiang H, Liu J, Ye J, Liu H, Xing S, Wu Y. Focal adhesion kinase serves as a marker of cervical lymph node metastasis and is a potential therapeutic target in tongue cancer. J Cancer Res Clin Oncol. 2010; 136: 295–302. https://doi.org/10.1007/s00432-010-0780-4 PMID: 20127254

20. Hu Q, Peng J, Chen X, Li H, Song M, Cheng B, et al. Obesity and genes related to lipid metabolism predict poor survival in oral squamous cell carcinoma. Oral Oncol. 2019; 89: 14–22. https://doi.org/10.1016/j.oraloncology.2018.12.006 PMID: 30732952

21. Morita Y, Hata K, Nakanishi M, Omata T, Morita N, Yura Y, et al. Cellular fibronectin 1 promotes VEGF-C expression, lymphangiogenesis and lymph node metastasis associated with human oral squamous cell carcinoma. Clin Exp Metastasis. 2015; 32: 739–53. https://doi.org/10.1007/s10432-015-9741-2 PMID: 26319373

22. Yu JS, Chen YT, Chiang WF, Hsiao YC, Chu LJ, See LC, et al. Saliva protein biomarkers to detect oral squamous cell carcinoma in a high-risk population in Taiwan. Proc Natl Acad Sci U.S.A. 2016; 113: 11549–11554. https://doi.org/10.1073/pnas.1612368113 PMID: 27663741

23. He B, Lin X, Tian F, Yu W, Qiao B. MiR-133a-3p Inhibits Oral Squamous Cell Carcinoma (OSCC) Proliferation and Invasion by Suppressing COLL1A1. J Cell Biochem. 2018; 119: 338–346. https://doi.org/10.1002/jcb.26182 PMID: 28569392

24. Agrawal N, Frederick MJ, Pickering CR, Bettegowda C, Chang K, Li RJ, et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science. 2011; 333:1154–7. https://doi.org/10.1126/science.1206923 PMID: 21798897
25. Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A, et al. The mutational landscape of head and neck squamous cell carcinoma. Science. 2011; 333:1157–60. https://doi.org/10.1126/science.1208130 PMID: 21798893

26. Nishikawa Y, Miyazaki T, Nakashiro K, Yamagata H, Isokawa M, Goda H, et al. Human FAT1 cadherin controls cell migration and invasion of oral squamous cell carcinoma through the localization of beta-catenin. Oncol Rep. 2011; 26:587–92. https://doi.org/10.3892/or.2011.1324 PMID: 21617878

27. Morris LG, Kaufman AM, Gong Y, Ramaswami D, Walsh LA, Turcan S, et al. Recurrent somatic mutation of FAT1 in multiple human cancers leads to aberrant Wnt activation. Nat Genet. 2013; 45:253–61. https://doi.org/10.1038/ng.2538 PMID: 23354438

28. Voelxen NF, Blatt S, Knopf P, Henkel M, Appelhans C, Righesso LAR, et al. Comparative metabolic analysis in head and neck cancer and the normal gingiva. Clin Oral Investig. 2018; 22: 1033–1043. https://doi.org/10.1007/s00784-017-2185-0 PMID: 28735466

29. Simões-Sousa S, Granja S, Pinheiro C, Fernandes D, Longatto-Filho A, Laus AC, et al. Prognostic significance of monocarboxylate transporter expression in oral cavity tumors. Cell Cycle. 2016; 15: 1865–73. https://doi.org/10.1080/15384101.2016.1188239 PMID: 27232157

30. Li Q, Qiu XM, Li QH, Wang XY, Li L, Xu M, et al. MicroRNA-424 may function as a tumor suppressor in endometrial carcinoma cells by targeting E2F7. Oncol Rep. 2015; 33: 2354–60. https://doi.org/10.3892/or.2015.3812 PMID: 25708247

31. Liu W, Song Y, Zhang C, Gao P, Huang B, Yang J. The protective role of all-transretinoic acid (ATRA) against colorectal cancer development is achieved via increasing miR-3666 expression and decreasing E2F7 expression. Biomed Pharmacother. 2018; 104: 94–101. https://doi.org/10.1016/j.biopha.2018.05.015 PMID: 29772445

32. Yin W, Wang B, Ding M, Huo Y, Hu H, Cai R, et al. Elevated E2F7 expression predicts poor prognosis in human patients with gliomas. J Clin Neurosci. 2016; 33: 187–193. https://doi.org/10.1016/j.jocn.2016.04.019 PMID: 27460513

33. Shan B, Dong M, Tang H, Wang N, Zhang J, Yan C, et al. Voltage-gated sodium channels were differentially expressed in human normal prostate, benign prostatic hyperplasia and prostate cancer cells. Oncol Lett. 2014; 8: 345–350. https://doi.org/10.3892/ol.2014.2110 PMID: 24992974

34. Hernandez-Plata E, Ortiz CS, Marquina-Castillo B, Medina-Martinez I, Alfaro A, Berumen J, et al. Overexpression of NaV 1.6 channels is associated with the invasion capacity of human cervical cancer. Int J Cancer. 2012; 130: 350–357. https://doi.org/10.1002/ijc.26210 PMID: 21630263

35. Patel F, Brackenbury WJ. Dual roles of voltage-gated sodium channels in development and cancer. Int J Dev Biol. 2015; 59: 357–66. https://doi.org/10.1387/ijdb.150171wb PMID: 26009234

36. Lu SX, Zhang CZ, Luo RZ, Wang CH, Liu LL, Fu J, et al. Zic2 promotes tumor growth and metastasis via PAK4 in hepatocellular carcinoma. Cancer Lett. 2017; 402: 71–80. https://doi.org/10.1016/j.canlet.2017.05.018 PMID: 28577975

37. Huang S, Jin A. ZIC2 promotes viability and invasion of human osteosarcoma cells by suppressing SHIP2 expression and activating PI3K/AKT pathways. J Cell Biochem. 2018; 119: 2248–2257. https://doi.org/10.1002/jcb.26387 PMID: 28857346

38. Sakuma K, Kasamatsu A, Yamatogi M, Yamano Y, Fushimi K, Iyoda M, et al. Expression status of Zic family member 2 as a prognostic marker for oral squamous cell carcinoma. J Cancer Res Clin Oncol. 2010; 136: 553–9. https://doi.org/10.1007/s00432-009-0689-y PMID: 19784848

39. Rastogi B, Kumar A, Raut SK, Panda NK, Rattan V, Joshi N, et al. Downregulation of miR-377 Promotes Oral Squamous Cell Carcinoma Growth and Migration by Targeting HDAC9. Cancer Invest. 2017; 35: 152–162. https://doi.org/10.1080/07357907.2017.1286669 PMID: 28267394

40. Liu PY, Sheu JJ, Lin PC, Lin CT, Liu YJ, Ho LI, et al. Expression of Nur77 induced by an n-butyldi-n-ephthallid-nephallid derivative promotes apoptosis and inhibits cell growth in oral squamous cell carcinoma. Invest New Drugs. 2012; 30: 79–89. https://doi.org/10.1007/s10637-010-9518-z PMID: 20809206

41. Chen J, López-Moyado IF, Seo H, Lio C-WJ, Hempleman LJ, Sekiya T, et al. NR4A transcription factors limit CAR T cell function in solid tumours. Nature. 2019; 567:530–4. https://doi.org/10.1038/s41586-019-0985-x PMID: 30814732

42. Liu X, Wang Y, Lu H, Li J, Yan X, Xiao M, et al. Genome-wide analysis identifies NR4A1 as a key mediator of T cell dysfunction. Nature. 2019; 567:525–9. https://doi.org/10.1038/s41586-019-0979-8 PMID: 30814730

43. Hakami F, Darda L, Stafford P, Woll P, Lambert DW, Hunter KD, et al. The roles of HOXD10 in the development and progression of head and neck squamous cell carcinoma (HNSSC). Br J Cancer. 2014; 111: 807–16. https://doi.org/10.1038/bjc.2014.372 PMID: 25010866
44. Zhang R, Leng H, Huang J, Du Y, Wang Y, Zang W, et al. miR-337 regulates the proliferation and invasion in pancreatic ductal adenocarcinoma by targeting HOXB7. Diagn Pathol. 2014; 9: 171. https://doi.org/10.1186/s13000-014-0171-2 PMID: 25183455

45. Xiang X, Mei H, Zhao X, Pu J, Li D, Qu H, et al. miRNA-337-3p suppresses neuroblastoma progression by repressing the transcription of matrix metalloproteinase 14. Oncotarget. 2015; 6: 22452–66. https://doi.org/10.18632/oncotarget.4311 PMID: 26084291

46. Cai Y, He T, Liang L, Zhang X, Yuan H. Upregulation of microRNA-337 promotes the proliferation of endometrial carcinoma cells via targeting PTEN. Mol Med Rep. 2016; 13: 4827–34. https://doi.org/10.3892/mmr.2016.5134 PMID: 27082228

47. Wang Z, Wang J, Yang Y, Hao B, Wang R, Li Y, et al. Loss of has-miR-337-3p expression is associated with lymph node metastasis of human gastric cancer. J Exp Clin Cancer Res. 2013; 32: 76. https://doi.org/10.1186/1756-9966-32-76 PMID: 24422944

48. Pickering CR, Zhang J, Yoo SY, Bengtsson L, Moorthy S, Neskey DM, et al. Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers. Cancer Discov. 2013; 3: 770–81. https://doi.org/10.1158/2159-8290.CD-12-0537 PMID: 23619168

49. The Cancer Genome Atlas Research N, Bell D, Berchuck A, Birrer M, Cramer DW, et al. Integrated genomic analyses of ovarian carcinoma. Nature. 2011; 474:609. https://doi.org/10.1038/nature10166 PMID: 21720365

50. Kazemi-Oula G, Ghafouri-Fard S, Mobasher MB, Geranpayeh L, Modarressi MH. Upregulation of RHOXF2 and ODF4 Expression in Breast Cancer Tissues. Cell J. 2015; 17: 471–7. https://doi.org/10.22074/cellj.2015.8 PMID: 26464818

51. Afsharpad M, Nowroozzi MR, Mobasher MB, Ayati M, Nekoohesh L, Saffari M, et al. Cancer-Testis Antigens as New Candidate Diagnostic Biomarkers for Transitional Cell Carcinoma of Bladder. Pathol Oncol Res. 2019; 25: 191–199. https://doi.org/10.1007/s12253-017-0313-4 PMID: 29058301

52. Zhang T, Zhao D, Wang Q, Yu X, Cui Y, Guo L, et al. MicroRNA-1322 regulates ECRG2 allele specifically and acts as a potential biomarker in patients with esophageal squamous cell carcinoma. Mol Carcinog. 2013; 52: 581–90. https://doi.org/10.1002/mc.21880 PMID: 22315007

53. Cheng X, Shen Z, Yin L, Lu SH, Cui Y. ECRG2 regulates cell migration/invasion through urokinase-type plasmin activator receptor (uPAR)/beta1 integrin pathway. J Biol Chem. 2009; 284: 30897–906. https://doi.org/10.1074/jbc.M109.011213 PMID: 19717562

54. Hou XF, Xu LP, Song HY, Li S, Wu C, Wang JF. enhances the anti-cancer effects of cisplatin in cisplatin-resistant esophageal cancer cells upregulation of and downregulation of. World J Gastroenterol. 2017; 23: 1796–1803. https://doi.org/10.3748/wjg.v23.i10.1796 PMID: 2834885

55. Song H, Song C, Wang H, Li C, Yang F, Lu SH, et al. Suppression of hepatocarcinoma model in vitro and in vivo by ECRG2 delivery using adenoviral vector. Cancer Gene Ther. 2012; 19: 875–9. https://doi.org/10.1038/cgt.2012.77 PMID: 23079671

56. Li F, Yoshizawa JM, Kim KM, Kanjanapangka J, Grogan TR, Wang X, et al. Discovery and Validation of Salivary Extracellular RNA Biomarkers for Noninvasive Detection of Gastric Cancer. Clin Chem. 2018; 64: 1513–1521. https://doi.org/10.1373/clinchem.2018.290569 PMID: 30097497

57. Feng L, Houck JR, Lohavanichbut P, Chen C. Transcriptome analysis reveals differentially expressed IncRNAs between oral squamous cell carcinoma and healthy oral mucosa. Oncotarget. 2017; 8: 31521–31531. https://doi.org/10.18632/oncotarget.16358 PMID: 28415559

58. Xu K, Tian H, Zhao S, Yuan D, Jiang L, Liu X, et al. Long Noncoding RNA LOC441178 Reduces the Invasion and Migration of Squamous Carcinoma Cells by Targeting ROCK1. Biomed Res Int. 2018; 2018: 4357647. https://doi.org/10.1155/2018/4357647 PMID: 30364063